Randomized, Double Blind, Controlled Phase II Trial of the Safety, Tolerability and Immunogenicity of Fluzone Inactivated Trivalent Influenza Virus Vaccine Administered With and Without JVRS-100 Adjuvant in Subjects 65 Years and Older.

Trial Profile

Randomized, Double Blind, Controlled Phase II Trial of the Safety, Tolerability and Immunogenicity of Fluzone Inactivated Trivalent Influenza Virus Vaccine Administered With and Without JVRS-100 Adjuvant in Subjects 65 Years and Older.

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Feb 2011

At a glance

  • Drugs Influenza virus vaccine; JVRS 100
  • Indications Influenza virus infections
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Juvaris BioTherapeutics
  • Most Recent Events

    • 11 Feb 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 16 Mar 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 28 Jan 2010 The trial is expected to be completed in mid-2010, according to a Juvaris BioTherapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top